Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I

被引：0
|
作者：
Jean-Marie Martinez
Aurélie Brunet
Fabrice Hurbin
A. Thomas DiCioccio
Clémence Rauch
David Fabre
机构：
[1] Sanofi,TMED/PKDM Department
[2] Regeneron Pharmaceuticals,undefined
[3] Inc.,undefined
来源：
Clinical Pharmacokinetics | 2019年 / 58卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：101 / 113
页数：12
相关论文
共 6 条
  • [1] Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition ModelSupport for a Biologics License Application Submission: Part I
    Martinez, Jean-Marie
    Brunet, Aurelie
    Hurbin, Fabrice
    DiCioccio, A. Thomas
    Rauch, Clemence
    Fabre, David
    CLINICAL PHARMACOKINETICS, 2019, 58 (01) : 101 - 113
  • [2] Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II
    Xavier Nicolas
    Nassim Djebli
    Clémence Rauch
    Aurélie Brunet
    Fabrice Hurbin
    Jean-Marie Martinez
    David Fabre
    Clinical Pharmacokinetics, 2019, 58 : 115 - 130
  • [3] Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II
    Nicolas, Xavier
    Djebli, Nassim
    Rauch, Clemence
    Brunet, Aurelie
    Hurbin, Fabrice
    Martinez, Jean-Marie
    Fabre, David
    CLINICAL PHARMACOKINETICS, 2019, 58 (01) : 115 - 130
  • [4] Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies
    Djebli, Nassim
    Martinez, Jean-Marie
    Lohan, Laura
    Khier, Sonia
    Brunet, Aurelie
    Hurbin, Fabrice
    Fabre, David
    CLINICAL PHARMACOKINETICS, 2017, 56 (10) : 1155 - 1171
  • [5] Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies
    Nassim Djebli
    Jean-Marie Martinez
    Laura Lohan
    Sonia Khier
    Aurélie Brunet
    Fabrice Hurbin
    David Fabre
    Clinical Pharmacokinetics, 2017, 56 : 1155 - 1171
  • [6] Target-Mediated Drug Disposition (TMDD) Population Pharmacokinetics (PopPK) Model Using the Quasi-Steady-State (QSS) Approximation of Alirocumab in Healthy Volunteers or Patients: Pooled Analysis of Randomized Phase I/II/III Studies
    Djebli, Nassim
    Martinez, Jean-Marie
    Lohan, Laura
    Khier, Sonia
    Brunet, Aurelie
    Hurbin, Fabrice
    Fabre, David
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S109 - S110
1